DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
HKI-357 is an investigational drug.
There have been 22 clinical trials for HKI-357. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Puma Biotechnology, Inc., Dana-Farber Cancer Institute, and Translational Breast Cancer Research Consortium.
Recent Clinical Trials for HKI-357
|HKI-272 for HER2-Positive Breast Cancer and Brain Metastases||Translational Breast Cancer Research Consortium||Phase 2|
|HKI-272 for HER2-Positive Breast Cancer and Brain Metastases||Dana-Farber Cancer Institute||Phase 2|
|Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer||Puma Biotechnology, Inc.||Phase 2|